Identification

Name
Fimasartan
Accession Number
DB09279
Type
Small Molecule
Groups
Approved, Investigational
Description

Fimasartan is a non-peptide angiotensin II receptor antagonist (ARB) used for the treatment of hypertension and heart failure. Concurrent administration of fimasartan with diuretic hydrochlorothiazide has shown to be safe in clinical trials. Fimasartan was approved for use in South Korea in September 9th, 2010 and is available under the brand name Kanarb through Boryung Pharmaceuticals, who are presently seeking worldwide partnership.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Fimasartan potassium trihydrate4516BN0T4B1020110-23-9IJEKJHQBGZFMMI-UHFFFAOYSA-N
International/Other Brands
Kanarb (Boryung Pharmaceuticals)
Categories
UNII
P58222188P
CAS number
247257-48-3
Weight
Average: 501.65
Monoisotopic: 501.23107982
Chemical Formula
C27H31N7OS
InChI Key
AMEROGPZOLAFBN-UHFFFAOYSA-N
InChI
InChI=1S/C27H31N7OS/c1-5-6-11-24-28-18(2)23(16-25(36)33(3)4)27(35)34(24)17-19-12-14-20(15-13-19)21-9-7-8-10-22(21)26-29-31-32-30-26/h7-10,12-15H,5-6,11,16-17H2,1-4H3,(H,29,30,31,32)
IUPAC Name
2-(2-butyl-4-methyl-6-oxo-1-{[2'-(1H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1,6-dihydropyrimidin-5-yl)-N,N-dimethylethanethioamide
SMILES
CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1

Pharmacology

Indication

Used for the treatment of hypertension and heart failure [1].

Structured Indications
Not Available
Pharmacodynamics

Fimasartan is a selective angiotensin receptor 1 (AR1) inhibitor [1]. It acts to lower blood pressure by inhibiting vasoconstriction

Mechanism of action

Angiotensin II activates AR1 leading to vasoconstriction and increased noradrenaline release which further increases vasoconstriction via action at α1-adrenergic receptors [1, 2]. It also stimulates secretion of aldosterone which acts to increase sodium and water reabsorption in the renal tubules [2]. Fimasartan bind to and antagonizes AR1 preventing vasoconstriction and reducing aldosterone secretion to increase natriuresis leading to a reduction in blood volume. Together these effects produce an anti-hypertensive effect.

TargetActionsOrganism
AType-1 angiotensin II receptor
antagonist
Human
Absorption

Tmax is 0.5-1.3 h [1].

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination

Most is eliminated unchangd in bile with less than 3% in the urine [1].

Half life

The half life of elimination is 7-10 h [1].

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcebutololThe risk or severity of adverse effects can be increased when Fimasartan is combined with Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Fimasartan is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Fimasartan is combined with Acemetacin.Approved, Experimental, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Fimasartan is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Fimasartan is combined with Adapalene.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Fimasartan is combined with Alclofenac.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Fimasartan is combined with Aldesleukin.Approved
AliskirenAliskiren may increase the hyperkalemic activities of Fimasartan.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Fimasartan is combined with Alminoprofen.Experimental
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Fimasartan.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Fimasartan is combined with Amiloride.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Fimasartan.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Fimasartan.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Fimasartan.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Fimasartan is combined with Amyl Nitrite.Approved
AndrographolideThe risk or severity of adverse effects can be increased when Fimasartan is combined with Andrographolide.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Antipyrine.Approved
ApocyninThe risk or severity of adverse effects can be increased when Fimasartan is combined with Apocynin.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Fimasartan.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Apraclonidine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Fimasartan is combined with Apremilast.Approved, Investigational
ArdeparinArdeparin may increase the hyperkalemic activities of Fimasartan.Approved, Investigational, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Fimasartan.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Fimasartan.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Fimasartan.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Fimasartan is combined with Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Fimasartan is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Fimasartan is combined with Azilsartan medoxomil.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Fimasartan is combined with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Fimasartan.Experimental
BarbitalBarbital may increase the hypotensive activities of Fimasartan.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Fimasartan.Approved
BemiparinBemiparin may increase the hyperkalemic activities of Fimasartan.Approved, Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Fimasartan is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Fimasartan is combined with Bendazac.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Fimasartan is combined with Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Fimasartan is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Fimasartan is combined with Benoxaprofen.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Benzydamine.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Fimasartan.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Fimasartan is combined with Betaxolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Fimasartan is combined with Bevonium.Experimental
BisoprololThe risk or severity of adverse effects can be increased when Fimasartan is combined with Bisoprolol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Fimasartan.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Fimasartan is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Brimonidine.Approved
BromfenacThe risk or severity of adverse effects can be increased when Fimasartan is combined with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fimasartan.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Bucillamine.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Fimasartan is combined with Bufexamac.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Fimasartan is combined with Bumadizone.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Fimasartan is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fimasartan.Approved, Investigational
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Fimasartan.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Fimasartan is combined with Candesartan cilexetil.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Fimasartan is combined with Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Fimasartan is combined with Captopril.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Fimasartan.Approved
CarprofenThe risk or severity of adverse effects can be increased when Fimasartan is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Fimasartan is combined with Carteolol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Fimasartan is combined with Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Fimasartan is combined with Celecoxib.Approved, Investigational
CertoparinCertoparin may increase the hyperkalemic activities of Fimasartan.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Fimasartan is combined with Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fimasartan.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Fimasartan is combined with Chlorthalidone.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Fimasartan is combined with Choline magnesium trisalicylate.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Fimasartan is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Fimasartan.Approved, Investigational
CiprofloxacinFimasartan may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
ClevidipineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Fimasartan.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Fimasartan.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Clonidine.Approved
ClonixinThe risk or severity of adverse effects can be increased when Fimasartan is combined with Clonixin.Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Fimasartan.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Fimasartan.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Fimasartan is combined with Curcumin.Investigational
CyclosporineThe serum concentration of Fimasartan can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Fimasartan is combined with D-Limonene.Investigational
DalteparinDalteparin may increase the hyperkalemic activities of Fimasartan.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Fimasartan is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Fimasartan.Investigational
DelaprilThe risk or severity of adverse effects can be increased when Fimasartan is combined with Delapril.Experimental
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Fimasartan.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Dexmedetomidine.Approved, Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Fimasartan is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Fimasartan is combined with Diclofenamide.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Fimasartan is combined with Difenpiramide.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Fimasartan is combined with Diflunisal.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Fimasartan is combined with Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Fimasartan is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Fimasartan is combined with Dipyridamole.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Fimasartan is combined with Doxazosin.Approved
DrospirenoneFimasartan may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Fimasartan is combined with Droxicam.Approved
DuloxetineFimasartan may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Fimasartan is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Fimasartan is combined with E-6201.Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Fimasartan.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Fimasartan is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Fimasartan is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Fimasartan is combined with Enalaprilat.Approved
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Fimasartan.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Fimasartan is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Fimasartan.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Fimasartan.Approved
EprosartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Eprosartan.Approved
EsmololThe risk or severity of adverse effects can be increased when Fimasartan is combined with Esmolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Fimasartan is combined with Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Fimasartan is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Fimasartan is combined with Ethenzamide.Experimental
EtodolacThe risk or severity of adverse effects can be increased when Fimasartan is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Fimasartan is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Fimasartan is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Fimasartan is combined with Evening primrose oil.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when Fimasartan is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Fimasartan is combined with Felbinac.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fimasartan is combined with Fenbufen.Approved
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Fimasartan.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fimasartan is combined with Fenoprofen.Approved
FentiazacThe risk or severity of adverse effects can be increased when Fimasartan is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Fimasartan is combined with Feprazone.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Fimasartan is combined with Ferulic acid.Experimental
FloctafenineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Floctafenine.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Fimasartan is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Fimasartan is combined with Flunoxaprofen.Experimental
FlurbiprofenThe risk or severity of adverse effects can be increased when Fimasartan is combined with Flurbiprofen.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fimasartan is combined with Fosinopril.Approved
FurosemideThe risk or severity of adverse effects can be increased when Fimasartan is combined with Furosemide.Approved, Vet Approved
GuacetisalThe risk or severity of adverse effects can be increased when Fimasartan is combined with Guacetisal.Experimental
GuanfacineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Guanfacine.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Fimasartan is combined with Halothane.Approved, Vet Approved
HeparinHeparin may increase the hyperkalemic activities of Fimasartan.Approved, Investigational
HexobarbitalHexobarbital may increase the hypotensive activities of Fimasartan.Approved
HigenamineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Higenamine.Investigational
HydralazineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Fimasartan is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Fimasartan is combined with Hydroflumethiazide.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Fimasartan is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Fimasartan is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Fimasartan is combined with Icatibant.Approved
IloprostThe risk or severity of adverse effects can be increased when Fimasartan is combined with Iloprost.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Fimasartan is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Fimasartan is combined with Imidazole salicylate.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Imipramine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Fimasartan is combined with Indapamide.Approved
IndobufenThe risk or severity of adverse effects can be increased when Fimasartan is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Fimasartan is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Fimasartan is combined with Indoprofen.Withdrawn
IndoraminThe risk or severity of adverse effects can be increased when Fimasartan is combined with Indoramin.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Irbesartan.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Fimasartan is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Fimasartan is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Fimasartan is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Fimasartan is combined with Isosorbide Mononitrate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Fimasartan is combined with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Isradipine.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Fimasartan is combined with Kebuzone.Experimental
KetoconazoleThe serum concentration of Fimasartan can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Fimasartan is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Fimasartan is combined with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Fimasartan is combined with Labetalol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Lacidipine.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Fimasartan is combined with Leflunomide.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Fimasartan is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Levobupivacaine.Approved, Investigational
LevodopaFimasartan may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Levosimendan.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Fimasartan is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Fimasartan.Approved
LofexidineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Lofexidine.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Fimasartan is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Fimasartan is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Losartan.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Fimasartan is combined with Loxoprofen.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Fimasartan is combined with Lumiracoxib.Approved, Investigational
Magnesium salicylateThe risk or severity of adverse effects can be increased when Fimasartan is combined with Magnesium salicylate.Approved
MannitolThe risk or severity of adverse effects can be increased when Fimasartan is combined with Mannitol.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Fimasartan is combined with Masoprocol.Approved, Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Mecamylamine.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Fimasartan is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Fimasartan is combined with Mefenamic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Fimasartan is combined with Meloxicam.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Fimasartan is combined with Metamizole.Investigational, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Fimasartan is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Fimasartan.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Fimasartan is combined with Methyclothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Fimasartan is combined with Methyldopa.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Fimasartan.Approved
MetipranololThe risk or severity of adverse effects can be increased when Fimasartan is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Fimasartan is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Fimasartan is combined with Metoprolol.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Fimasartan is combined with Minoxidil.Approved
MizoribineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Fimasartan is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Fimasartan is combined with Mofebutazone.Experimental
MorphineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Morphine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Moxonidine.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Fimasartan is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Fimasartan is combined with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nabilone.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nadolol.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Fimasartan.Approved
NafamostatThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Naftifine.Approved
NaproxenThe risk or severity of adverse effects can be increased when Fimasartan is combined with Naproxen.Approved, Vet Approved
NebivololThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nebivolol.Approved, Investigational
NepafenacThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nesiritide.Approved, Investigational
NicardipineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Fimasartan.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nifedipine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Fimasartan is combined with Niflumic Acid.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nitric Oxide.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nitroprusside.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Fimasartan is combined with Obinutuzumab.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Olmesartan.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Olsalazine.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Fimasartan is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Fimasartan is combined with Orgotein.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Fimasartan is combined with Oxaprozin.Approved
OxprenololThe risk or severity of adverse effects can be increased when Fimasartan is combined with Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Fimasartan is combined with Oxyphenbutazone.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Fimasartan is combined with Paclitaxel.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Papaverine.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Fimasartan is combined with Parecoxib.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Fimasartan.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Fimasartan is combined with Parthenolide.Investigational
PenbutololThe risk or severity of adverse effects can be increased when Fimasartan is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Fimasartan.Approved, Vet Approved
PerindoprilThe risk or severity of adverse effects can be increased when Fimasartan is combined with Perindopril.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Phenelzine.Approved
PhenobarbitalPhenobarbital may increase the hypotensive activities of Fimasartan.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Phenoxybenzamine.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Phentolamine.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Fimasartan is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Fimasartan is combined with Pimecrolimus.Approved, Investigational
PindololThe risk or severity of adverse effects can be increased when Fimasartan is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Fimasartan is combined with Pipamperone.Approved, Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Fimasartan is combined with Pirfenidone.Approved, Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Fimasartan is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Fimasartan is combined with Pirprofen.Experimental
PramipexoleThe risk or severity of adverse effects can be increased when Fimasartan is combined with Pramipexole.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Fimasartan is combined with Pranoprofen.Experimental, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Fimasartan is combined with Prazosin.Approved
PrimidonePrimidone may increase the hypotensive activities of Fimasartan.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Fimasartan is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Fimasartan is combined with Propacetamol.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Fimasartan is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Fimasartan is combined with Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Fimasartan is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Fimasartan is combined with Proquazone.Experimental
PTC299The risk or severity of adverse effects can be increased when Fimasartan is combined with PTC299.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Fimasartan is combined with Quinapril.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Fimasartan is combined with Ramipril.Approved
RasagilineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Fimasartan is combined with Remifentanil.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Reserpine.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Fimasartan is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Fimasartan.Approved, Investigational
RifampicinThe serum concentration of Fimasartan can be increased when it is combined with Rifampicin.Approved
RiociguatThe risk or severity of adverse effects can be increased when Fimasartan is combined with Riociguat.Approved
RisperidoneFimasartan may increase the hypotensive activities of Risperidone.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Fimasartan is combined with Rofecoxib.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Fimasartan is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Fimasartan is combined with Sacubitril.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Fimasartan is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Fimasartan is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Fimasartan is combined with Salsalate.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Fimasartan.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Selegiline.Approved, Investigational, Vet Approved
SemapimodThe risk or severity of adverse effects can be increased when Fimasartan is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Fimasartan is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Fimasartan is combined with Serrapeptase.Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Fimasartan is combined with Sevoflurane.Approved, Vet Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Fimasartan is combined with Sodium Nitrite.Approved
Sodium phosphateFimasartan may increase the nephrotoxic activities of Sodium phosphate.Approved
SotalolThe risk or severity of adverse effects can be increased when Fimasartan is combined with Sotalol.Approved
SpiraprilThe risk or severity of adverse effects can be increased when Fimasartan is combined with Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Fimasartan is combined with Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Fimasartan is combined with SRT501.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Fimasartan is combined with Streptokinase.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Fimasartan is combined with Sufentanil.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Fimasartan is combined with Sulindac.Approved
SuprofenThe risk or severity of adverse effects can be increased when Fimasartan is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Fimasartan is combined with Suxibuzone.Experimental
TamsulosinThe risk or severity of adverse effects can be increased when Fimasartan is combined with Tamsulosin.Approved, Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Fimasartan is combined with Tarenflurbil.Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Telmisartan.Approved, Investigational
TemocaprilThe risk or severity of adverse effects can be increased when Fimasartan is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Fimasartan is combined with Tenidap.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Fimasartan is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Fimasartan is combined with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Fimasartan is combined with Terazosin.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Fimasartan is combined with Teriflunomide.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Fimasartan is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Fimasartan.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Fimasartan.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Thioridazine.Approved, Withdrawn
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Fimasartan is combined with Tiaprofenic acid.Approved
TimololThe risk or severity of adverse effects can be increased when Fimasartan is combined with Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Fimasartan.Approved
TizanidineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Tizanidine.Approved
TolazolineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Fimasartan is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Fimasartan is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Fimasartan is combined with Tolmetin.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Fimasartan.Approved
TorasemideThe risk or severity of adverse effects can be increased when Fimasartan is combined with Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Fimasartan is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Fimasartan is combined with Tranilast.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Fimasartan is combined with Tranylcypromine.Approved
TretinoinThe risk or severity of adverse effects can be increased when Fimasartan is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Fimasartan is combined with Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Fimasartan is combined with Tribenoside.Experimental
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Fimasartan.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Fimasartan is combined with Triptolide.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Fimasartan is combined with Valdecoxib.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Valsartan.Approved, Investigational
VerapamilThe risk or severity of adverse effects can be increased when Fimasartan is combined with Verapamil.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Fimasartan is combined with Zaltoprofen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Fimasartan is combined with Zileuton.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Fimasartan is combined with Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Fimasartan is combined with Zomepirac.Withdrawn
Food Interactions
Not Available

References

General References
  1. Kim JH, Lee JH, Paik SH, Kim JH, Chi YH: Fimasartan, a novel angiotensin II receptor antagonist. Arch Pharm Res. 2012 Jul;35(7):1123-6. doi: 10.1007/s12272-012-0700-z. [PubMed:22864732]
  2. Rang, H. P. and Dale, M. M. (2012). Rang and Dale's Pharmacology (7th ed.). Edinburgh: Elsevier/Churchill Livingstone. [ISBN:978-0-7020-3471-8]
External Links
PubChem Compound
9870652
PubChem Substance
310265172
ChemSpider
8046343
BindingDB
50364573
ChEBI
136044
ChEMBL
CHEMBL1951143
Wikipedia
Fimasartan
ATC Codes
C09CA10 — Fimasartan

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers2
1CompletedNot AvailableHepatic Impairment / Hypertension,Essential1
1CompletedNot AvailableHigh Blood Pressure (Hypertension)5
1CompletedNot AvailableHypertension,Essential8
1CompletedNot AvailableImpaired Renal Function1
1CompletedOtherHigh Blood Pressure (Hypertension)2
1CompletedTreatmentHigh Blood Pressure (Hypertension) / Hyperlipidemias2
1CompletedTreatmentHypertension,Essential1
1RecruitingTreatmentHypertension, Hyperlipidemia1
2CompletedTreatmentHigh Blood Pressure (Hypertension)3
2CompletedTreatmentHypertension,Essential2
3CompletedTreatmentArterial Hypertension1
3CompletedTreatmentEssential Hypertension, Dyslipidemia1
3CompletedTreatmentHigh Blood Pressure (Hypertension)3
3CompletedTreatmentHypertension,Essential3
3Not Yet RecruitingTreatmentEssential Hypertension, Dyslipidemia1
3RecruitingTreatmentChronic Kidney Disease (CKD)1
3RecruitingTreatmentDyslipidemias / Hypertension,Essential1
4Active Not RecruitingTreatmentBlood Pressures / Stroke, Ischemic1
4Active Not RecruitingTreatmentCoronary Artery Disease1
4Active Not RecruitingTreatmentHigh Blood Pressure (Hypertension)1
4CompletedTreatmentEssential,Hypertension1
4CompletedTreatmentHigh Blood Pressure (Hypertension)2
4Unknown StatusTreatmentCritical Stenosis of Aortic Valve1
Not AvailableActive Not RecruitingNot AvailableHigh Blood Pressure (Hypertension)1
Not AvailableCompletedTreatmentDiabetes Mellitus (DM) / High Blood Pressure (Hypertension)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00469 mg/mLALOGPS
logP4.09ALOGPS
logP4.21ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)4.23ChemAxon
pKa (Strongest Basic)1.34ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area90.37 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity161.24 m3·mol-1ChemAxon
Polarizability54.86 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Biphenyls and derivatives
Direct Parent
Biphenyls and derivatives
Alternative Parents
Phenyltetrazoles and derivatives / Pyrimidones / Hydropyrimidines / Thioamides / Heteroaromatic compounds / Lactams / Thiocarboxylic acid amides / Azacyclic compounds / Thiocarbonyl compounds / Organopnictogen compounds
show 4 more
Substituents
Biphenyl / Phenyltetrazole / Pyrimidone / Hydropyrimidine / Pyrimidine / Azole / Heteroaromatic compound / Tetrazole / Thioamide / Lactam
show 13 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name
AGTR1
Uniprot ID
P30556
Uniprot Name
Type-1 angiotensin II receptor
Molecular Weight
41060.53 Da
References
  1. Kim JH, Lee JH, Paik SH, Kim JH, Chi YH: Fimasartan, a novel angiotensin II receptor antagonist. Arch Pharm Res. 2012 Jul;35(7):1123-6. doi: 10.1007/s12272-012-0700-z. [PubMed:22864732]

Drug created on October 29, 2015 09:04 / Updated on December 01, 2017 17:22